The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    March 2019

  • Pages
    501

  • View Count
    5392

Example Insights

Cell Encapsulation - Context Cell Encapsulation - Primary Research Cell Encapsulation - Patents
Cell Encapsulation Companies Cell Encapsulation Technologies Cell Encapsulation - Pharma players
Cell Encapsulation - Clinical trials Cell Encapsulation - Funding and Investments Cell Encapsulation - Partnerships and Collaborations
Cell Encapsulation - Partnerships Cell Encapsulation - Licensing Cell Encapsulation - Market Forecast

 

Overview

Encapsulated cell-based products are increasingly being investigated across a myriad of clinical applications, potentially overcoming a number of barriers associated with conventional treatment options

-- Chief Scientist, an Israel based small-sized company

Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018, more than 50% of the global population lives with some form of chronic illness. In 2018, the global prevalence of diabetes (considered to be one of the fastest-growing clinical conditions) was estimated to be around 425 million; likewise, around 450 million people worldwide are suffering from some form of mental health problem and / or neurological disorder. In addition, the World Health Organization (WHO) reported that different forms of cancers account for about 0.6 million deaths annually in the US alone. Over the years, advances in cell biology and regenerative medicine have led to the development of various cell-based therapies, which claim to possess the potential to address several unmet needs related to the treatment of different chronic clinical conditions. In fact, experts believe that mesenchymal stem cells may have the potential to improve patients' resistance to the ongoing novel COVID-19 infections. However, there are certain evident challenges, such as scarcity of viable donors, inherent immunogenicity, complications related to supply of oxygen / essential nutrients to grafted cells, drug delivery limitations, and the need for frequent re-administration of cells, which have so far restricted the use of cell-based interventions.

Extensive research on cell encapsulation strategies have enabled the development of a variety of technologies capable of confining therapeutic entities within biocompatible matrices / carriers. Encapsulated therapy products offer a myriad of advantages, and have been shown to be capable of addressing existing concerns related to cell sourcing, obviating the need for complex surgical procedures, and enabling targeted drug delivery without the need for immunosuppressive follow-on regimens. In fact, since 2013, over 3,000 patents have been published related to the aforementioned type of therapy, indicating the rapid pace of R&D activities in this domain. Stakeholders have also received significant support from both private and public investors. However, the commercial success of such products is still dependent on ongoing clinical studies, as no such therapy has yet been approved.
 

Scope of the Report

The ‘Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030’ report features an extensive study of the current market landscape and the future potential of encapsulated cell therapies and affiliated technologies. It is worth mentioning that the study also provides insights on therapy products wherein other active drug substances have been encapsulated within living cells. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of encapsulated cell therapies and affiliated technologies, highlighting various target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration, along with information on various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications. 
  • Comprehensive profiles of industry players that are currently engaged in the preclinical / clinical development of their proprietary encapsulated cell therapies, featuring an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key preclinical / clinical trial results. Each profile also includes a list of recent developments, highlighting the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the in the foreseen future.
  • An in-depth analysis of the patents that have been published related to cell encapsulation technologies, since 2013. The analysis also highlights the key trends associated with these patents, across patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, target therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
  • An analysis of the partnerships that have been established in the domain in the period 2013-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. The report also features a detailed study on the various grants that have been awarded to research institutes in this field.
  • An analysis highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers based on multiple parameters, such as therapeutic focus overlap, cell type overlap, research programs, existing collaborations, and developer strength

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates and expected pricing. The report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (eye disorders, metabolic disorders, neurological disorders, and oncological disorders), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapy products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Alexander Scheer (Chief Scientific Officer, Erytech Pharma)
  • Manuel Pires (Business Developer, Defymed)
  • Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem)
  • Mick McLean (Chief Executive Officer, Atelerix)
  • Quinton Oswald (Former President and Chief Executive Officer, Neurotech Pharmaceuticals)
  • William L Rust (Founder and Chief Executive Officer, Seraxis)
  • Yuval Avni (Former Chief Executive Officer, Beta-O2 Technologies)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of encapsulated cell therapies and affiliated technologies market in the mid to long term.

Chapter 3 is an introductory chapter that presents a general overview of cell-based therapies and the intricacies of their development and administration, along with information on the key challenges associated with them. Further, it features a detailed discussion on cell encapsulation, including a comprehensive history of development, and information on different types of cell encapsulation methods and materials. It also features a discussion on the key advantages / challenges associated with encapsulated cell therapies and affiliated technologies, providing information on their potential usability across different application areas. Further, the chapter features a discussion on the key growth drivers and road blocks related to cell encapsulation technologies and their use in treating various chronic conditions.

Chapter 4 includes information on more than 40 encapsulated cell therapies and affiliated technologies that are currently being developed by industry players for treating different chronic conditions. It features a comprehensive analysis of pipeline therapies and technologies, highlighting the target disease indications, phase of development, encapsulation method, type of cells / API, and route of administration. The chapter also highlights the contributions of various stakeholder companies that are developing novel encapsulation methods / techniques for use in storage and transportation of cells, as well as other applications. Additionally, the chapter features information on the initiatives undertaken by big pharmaceutical companies and academic players within this domain.
Chapter 5 includes elaborate profiles of industry players that are currently engaged in the clinical development of their proprietary encapsulated cell therapies for the treatment of metabolic disorders; each profile features an overview of the company, its financial information (if available), and a detailed description of its product(s), highlighting mechanism of action, current development status, and key clinical trial results. Each profile also includes a list of recent developments, the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. Further, for developers with early stage (preclinical) candidates, we have presented brief profiles, highlighting key details about the company, product portfolio, recent developments, and the likely roadmap / future plans related to the development and commercialization of their products (if available).
Chapter 6 includes elaborate profiles of industry players that are currently engaged in the clinical development of their proprietary encapsulated cell therapies for the treatment of non-metabolic disorders; each profile features an overview of the company, its financial information (if available), and a detailed description of its product (s), highlighting mechanism of action, current development status, and key clinical trial results. Each profile also includes a list of recent developments, the key milestones achieved, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future. Further, for developers with early stage (preclinical) candidates, we have presented brief profiles, highlighting key details about the company, product portfolio, recent developments, and the likely roadmap / future plans related to the development and commercialization of their products (if available).
Chapter 7 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been published since 2013 related to the cell encapsulation domain. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, emerging focus areas, leading industry players (in terms of number of patents filed / granted), and current intellectual property-related benchmarks and valuation.
Chapter 8 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various encapsulated cell therapies. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, leading industry and non-industry players (in terms of number of trials conducted), study design, targeted therapeutic area, key indications, study focus, clinical endpoints, and enrolled patient population and regional distribution of trials.
Chapter 9 features an elaborate discussion and analysis of partnerships / collaborations that have been established in the domain in the period 2013-2018. It includes a brief description of various types of partnership models (such as product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to encapsulated cell therapies and affiliated technologies. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 10 provides information on funding instances and investments that have been made within the cell encapsulation domain. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies between 2013 and 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.
Chapter 11 provides a detailed analysis of academic grants that have been awarded to support research related to encapsulated cell therapies and affiliated technologies. For the purpose of this analysis, we considered those academic grants that have been awarded within this domain since 2013. In addition to highlighting key funding institutes, the chapter provides several emerging encapsulation methods, target indications and type of cells, across which majority of the research work is currently focused. 
Chapter 12 features an insightful analysis, highlighting potential strategic partners (for instance, manufacturers) for encapsulated therapy developers, based on multiple parameters, such as therapeutic focus overlap, cell type overlap, researcg programs, existing collaborations, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to take their proprietary therapies / technologies from concept to the market with the help the appropriate partner entities.
Chapter 13 features a comprehensive market forecast, highlighting the future potential of this market till 2030 based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we have provided information on (potential) sales-based revenues generated by encapsulated cell therapies that are currently in late stages of development for the treatment of different chronic disorders, based on parameters, such as target consumer segments, likely adoption rates and expected pricing. The report features likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (eye disorders, metabolic disorders, neurological disorders, and oncological disorders), [B] target disease indications (ataxia telangiectasia, breast cancer, diabetes, glaucoma, head and neck cancer, macular telangectasia, pancreatic cancer, Parkinson's disease, and retinitis pigmentosa), [C] type of encapsulation material used (alginate-based microcapsules, cellulose hydrogels, medical-grade plastics, and red blood cells), and [D] key geographical regions (North America, Europe and Asia Pacific).
Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 15 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Alexander Scheer (Chief Scientific Officer, Erytech Pharma), Manuel Pires (Business Developer, Defymed), Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem), Mick McLean (Chief Executive Officer, Atelerix), Quinton Oswald (Former President and Chief Executive Officer, Neurotech Pharmaceuticals), William L Rust (Founder and Chief Executive Officer, Seraxis), and Yuval Avni (Former Chief Executive Officer, Beta-O2 Technologies).
Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.

 

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. An Overview of Cell Therapies
3.2.1. Cell Therapy Manufacturing 
3.2.2. Supply Chain 
3.2.3. Key Challenges 

3.3. An Introduction to Cell Encapsulation
3.3.1. Historical Overview 
3.3.2. Cell Encapsulation Approaches
3.3.3. Encapsulation Materials
3.3.4. Advantages and Challenges 

3.4. Potential Applications of Cell Encapsulation 
3.4.1. Targeted Drug / Therapy Delivery
3.4.2. Immunoprotection
3.4.3. Storage and Transportation

3.5. Key Growth Drivers and Road-blocks

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Encapsulated Cell Therapies and Encapsulation Technologies: Developer Landscape
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Size of Developers
4.2.4. Distribution by Type of Offering

4.3. Encapsulated Cell Therapies and Encapsulation Technologies: Development Pipeline
4.3.1. Distribution by Target Therapeutic Area
4.3.2. Distribution by Phase of Development
4.3.3. Distribution by Type of Cells and Other Encapsulated Components
4.3.4. Distribution by Type of Encapsulation Material Used
4.3.5. Distribution by Route of Administration
4.3.6. Distribution by Application Areas

4.5. Encapsulated Cell Therapies and Encapsulation Technologies: Initiatives of Big Pharmaceutical Players

5. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR METABOLIC DISORDERS: COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Clinical Candidates
5.2.1. Beta-O2 Technologies
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Product Description: ꞵAir Bio-artificial Pancreas
5.2.1.4. Recent Developments and Future Outlook

5.2.2. Diatranz Otsuka
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Product Description: DIABECELL®
5.2.2.4. Recent Developments and Future Outlook

5.2.3. Sernova
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Product Description: Cell Pouch System™
5.2.3.4. Recent Developments and Future Outlook

5.2.4. ViaCyte
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Product Description: PEC-Direct™ and PEC-Encap™
5.2.4.4. Recent Developments and Future Outlook

5.3. Developers with Preclinical Candidates
5.3.1. Company 1
5.3.2. Company 2
5.3.3. Betalin Therapeutics
5.3.4. Company 4
5.3.5. Defymed
5.3.6. Company 6
5.3.7. Company 7
5.3.8. Kadimastem
5.3.9. Company 9
5.3.10. Seraxis
5.3.11. Company 11
5.3.12. Company 12

6. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR NON-METABOLIC DISORDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Developers with Clinical Candidates
6.2.1. Azellon Cell Therapeutics
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: Cell Bandage
6.2.1.4. Recent Developments and Future Outlook

6.2.2. EryDel
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: EryDex System
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Erytech Pharma
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: GRASPA®
6.2.3.4. Recent Developments and Future Outlook

6.2.4. Gloriana Therapeutics
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: EC-NGF
6.2.4.4. Recent Developments and Future Outlook

6.2.5. Living Cell Technologies
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Product Description: NTCELL®
6.2.5.4. Recent Developments and Future Outlook

6.2.6. MaxiVAX
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MVX-ONCO-1
6.2.6.4. Recent Developments and Future Outlook

6.2.7. Neurotech Pharmaceuticals
6.2.7.1. Company Overview
6.2.7.2. Financial Information
6.2.7.3. Product Description: NT-501
6.2.7.4. Recent Developments and Future Outlook

6.2.8. PharmaCyte Biotech
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: Cell-in-a-Box®
6.2.8.4. Recent Developments and Future Outlook

6.3. Developers with Preclinical Candidates
6.3.1. Company 1
6.3.2. Sernova
6.3.3. Company 3

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Geographical Location
7.3.3. Analysis by CPC Classifications
7.3.4. Emerging Focus Areas
7.3.5. Leading Players: Analysis by Number of Patents

7.4. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Benchmarking Analysis (Industry Players)
7.4.1. Analysis by Patent Characteristics
7.4.2. Analysis by Geographical Location

7.5. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Valuation Analysis
7.6. Leading Patents: Analysis by Number of Citations

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Encapsulated Cell Therapies and Encapsulation Technologies: List of Clinical Trials
8.3.1. Analysis by Trial Registration Year
8.3.2. Geographical Analysis by Number of Clinical Trials
8.3.3. Geographical Analysis by Enrolled Patient Population
8.3.4. Analysis by Phase of Development
8.3.5. Analysis by Study Design
8.3.6. Analysis by Type of Sponsor / Collaborator
8.3.7. Most Active Players: Analysis by Number of Registered Trials
8.3.8. Analysis by Trial Focus 
8.3.9. Analysis by Therapeutic Area
8.3.10. Analysis by Clinical Endpoints

9. RECENT PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Encapsulated Cell Therapies and Encapsulation Technologies: Recent Collaborations and Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Analysis by Type of Cells and Other Encapsulated Components
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Analysis by Regions
9.3.6.1. Most Active Players
9.3.6.2. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Encapsulated Cell Therapies and Encapsulation Technologies: Recent Funding Instances
10.3.1. Analysis by Number of Funding Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Indications
10.3.5. Analysis by Amount Invested across Different Type of Cells and Other Encapsulated Components
10.3.6. Most Active Players: Analysis by Amount Invested
10.3.7. Most Active Investors: Analysis by Number of Instances
10.3.8. Geographical Analysis of Amount Invested
10.4. Concluding Remarks

11. GRANT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants
11.3.1. Analysis by Project Start Year
11.3.2. Analysis by Focus Area
11.3.3. Analysis by Support Period
11.3.4. Analysis by Type of Grant
11.3.5. Analysis by Amount Awarded
11.3.6. Analysis by Study Section
11.3.7. Analysis by Therapeutic Area
11.3.8. Analysis by Type of Cells and Other Encapsulated Components
11.3.9. Analysis by Type of Encapsulation Material
11.3.10. Leading Funding Institutes: Analysis by Number of Grants
11.3.11. Leading Recipient Organizations: Analysis by Number of Grants

12. POTENTIAL STRATEGIC PARTNERS 
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Potential Strategic Partners for Cell Therapy Development
12.3.1. Opportunities in North America
12.3.1.1. Most Likely Partners for Cell Therapy Development
12.3.1.2. Likely Partners for Cell Therapy Development
12.3.1.3. Less Likely Partners for Cell Therapy Development

12.3.2. Opportunities in Europe
12.3.2.1. Most Likely Partners for Cell Therapy Development
12.3.2.2. Likely Partners for Cell Therapy Development
12.3.2.3. Less Likely Partners for Cell Therapy Development

12.3.3. Opportunities in Asia-Pacific and Rest of the World
12.3.3.1. Most Likely Partners for Cell Therapy Development
12.3.3.2. Likely Partners for Cell Therapy Development
12.3.3.3. Less Likely Partners for Cell Therapy Development

12.4. Potential Strategic Partners for Cell Therapy Manufacturing
12.4.1. Opportunities in North America
12.4.1.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.1.2. Likely Partners for Cell Therapy Manufacturing
12.4.1.3. Less Likely Partners for Cell Therapy Manufacturing

12.4.2. Opportunities in Europe
12.4.2.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.2.2. Likely Partners for Cell Therapy Manufacturing
12.4.2.3. Less Likely Partners for Cell Therapy Manufacturing

12.4.3. Opportunities in Asia-Pacific and Rest of the World
12.4.3.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.3.2. Likely Partners for Cell Therapy Manufacturing
12.4.3.3. Less Likely Partners for Cell Therapy Manufacturing

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Cell Encapsulation Technologies Market, 2019-2030

13.3.1. Cell Encapsulation Technologies Market by Upfront Payments, 2019-2030
13.3.2. Cell Encapsulation Technologies Market by Milestone Payments, 2019-2030

13.4. Overall Encapsulated Cell Therapies Market, till 2030
13.4.1. Encapsulated Cell Therapies Market: Distribution by Therapeutic Area
13.4.1.1. Encapsulated Cell Therapies Market for Eye Disorders, till 2030
13.4.1.2. Encapsulated Cell Therapies Market for Metabolic Disorders, till 2030
13.4.1.3. Encapsulated Cell Therapies Market for Neurological Disorders, till 2030
13.4.1.4. Encapsulated Cell Therapies Market for Oncological Disorders, till 2030

13.4.2. Encapsulated Cell Therapies Market: Distribution by Type of Encapsulation Material Used
13.4.2.1. Encapsulated Cell Therapies Market for Alginate-based Microcapsules, till 2030
13.4.2.2. Encapsulated Cell Therapies Market for Cellulose Hydrogels, till 2030
13.4.2.3. Encapsulated Cell Therapies Market for Medical-grade Plastics, till 2030
13.4.2.4. Encapsulated Cell Therapies Market for Red Blood Cells, till 2030

13.4.3. Encapsulated Cell Therapies Market: Distribution by Geography
13.4.3.1. Encapsulated Cell Therapies Market in North America, till 2030
13.4.3.2. Encapsulated Cell Therapies Market in Europe, till 2030
13.4.3.3. Encapsulated Cell Therapies Market in Asia-Pacific, till 2030

13.5. Encapsulated Cell Therapies for Eye Disorders: Distribution by Indication
13.5.1. Encapsulated Cell Therapies Market for Eye Disorders: Macular Telangectasia, till 2030
13.5.1.1. NT-501 (Neurotech Pharmaceuticals)
13.5.1.1.1. Target Patient Population
13.5.1.1.2. Sales Forecast
13.5.1.1.3. Geographical Distribution of Projected Opportunity
13.5.1.1.3.1. Projected Opportunity in the US
13.5.1.1.3.2. Projected Opportunity in EU5
13.5.1.1.3.3. Projected Opportunity in Rest of Europe
13.5.1.1.3.4. Projected Opportunity in Australia

13.5.2. Encapsulated Cell Therapies Market for Eye Disorders: Glaucoma, till 2030
13.5.2.1. NT-501 (Neurotech Pharmaceuticals)
13.5.2.1.1. Target Patient Population
13.5.2.1.2. Sales Forecast
13.5.2.1.3. Geographical Distribution of Projected Opportunity
13.5.2.1.3.1. Projected Opportunity in the US
13.5.2.1.3.2. Projected Opportunity in EU5
13.5.2.1.3.3. Projected Opportunity in Rest of Europe
13.5.2.1.3.4. Projected Opportunity in Australia

13.5.3.  Encapsulated Cell Therapies Market for Eye Disorders: Retinitis Pigmentosa, till 2030
13.5.3.1. NT-501 (Neurotech Pharmaceuticals)
13.5.3.1.1. Target Patient Population
13.5.3.1.2. Sales Forecast
13.5.3.1.3. Geographical Distribution of Projected Opportunity
13.5.3.1.3.1. Projected Opportunity in the US
13.5.3.1.3.2. Projected Opportunity in EU5
13.5.3.1.3.3. Projected Opportunity in Rest of Europe
13.5.3.1.3.4. Projected Opportunity in Australia

13.6. Encapsulated Cell Therapies for Metabolic Disorders: Distribution by Indication
13.6.1. Encapsulated Cell Therapies Market for Metabolic Disorders: Type 1 Diabetes, till 2030
13.6.1.1. DIABECELL® (Diatranz Otsuka)
13.6.1.1.1. Target Patient Population
13.6.1.1.2. Sales Forecast
13.6.1.1.3. Geographical Distribution of Projected Opportunity
13.6.1.1.3.1. Projected Opportunity in the US
13.6.1.1.3.2. Projected Opportunity in Japan
13.6.1.1.3.3. Projected Opportunity in EU5
13.6.1.1.3.4. Projected Opportunity in Rest of Europe
13.6.1.1.3.5. Projected Opportunity in Australia
13.6.1.1.3.6. Projected Opportunity in New Zealand

13.7. Encapsulated Cell Therapies for Neurological Disorders: Distribution by Indication
13.7.1. Encapsulated Cell Therapies Market for Neurological Disorders: Ataxia Telangiectasia, till 2030
13.7.1.1. EryDex System (EryDel)
13.7.1.1.1. Target Patient Population
13.7.1.1.2. Sales Forecast
13.7.1.1.3. Geographical Distribution of Projected Opportunity
13.7.1.1.3.1. Projected Opportunity in EU5
13.7.1.1.3.2. Projected Opportunity in Rest of Europe
13.7.1.1.3.3. Projected Opportunity in the US
13.7.1.1.3.4. Projected Opportunity in Australia
13.7.1.1.3.5. Projected Opportunity in India
13.7.1.1.3.6. Projected Opportunity in Israel
13.7.1.1.3.7. Projected Opportunity in Tunisia

13.7.2. Encapsulated Cell Therapies Market for Neurological Disorders: Parkinson’s Disease, till 2030
13.7.2.1. NTCELL® (Living Cell Technologies)
13.7.2.2. Target Patient Population
13.7.2.2.1. Sales Forecast
13.7.2.2.2. Geographical Distribution of Projected Opportunity
13.7.2.2.2.1. Projected Opportunity in New Zealand
13.7.2.2.2.2. Projected Opportunity in the US
13.7.2.2.2.3. Projected Opportunity in Australia
13.7.2.2.2.4. Projected Opportunity in EU5
13.7.2.2.2.5. Projected Opportunity in Rest of Europe

13.8. Encapsulated Cell Therapies for Oncological Disorders: Distribution by Indication
13.8.1. Encapsulated Cell Therapies Market for Oncological Disorders: Pancreatic Cancer, till 2030
13.8.1.1. GRASPA® (Erytech Pharma)
13.8.1.1.1. Target Patient Population
13.8.1.1.2. Sales Forecast
13.8.1.1.3. Geographical Distribution of Projected Opportunity
13.8.1.1.3.1. Projected Opportunity in EU5
13.8.1.1.3.2. Projected Opportunity in Rest of Europe
13.8.1.1.3.3. Projected Opportunity in the US

13.8.2. Encapsulated Cell Therapies Market for Oncological Disorders: Non-Metastatic Pancreatic Cancer, till 2030
13.8.2.1. Cell-in-a-Box® (PharmaCyte Biotech)
13.8.2.1.1. Target Patient Population
13.8.2.1.2. Sales Forecast
13.8.2.1.3. Geographical Distribution of Projected Opportunity
13.8.2.1.3.1. Projected Opportunity in the US
13.8.2.1.3.2. Projected Opportunity in EU5
13.8.2.1.3.3. Projected Opportunity of Cell-in-a-Box in Rest of Europe

13.8.3. Encapsulated Cell Therapies Market for Oncological Disorders: Triple Negative Breast Cancer, till 2030
13.8.3.1. GRASPA (Erytech Pharma)
13.8.3.1.1. Target Patient Population
13.8.3.1.2. Sales Forecast
13.8.3.1.3. Geographical Distribution of Projected Opportunity
13.8.3.1.3.1. Projected Opportunity in EU5
13.8.3.1.3.2. Projected Opportunity in Rest of Europe
13.8.3.1.3.3. Projected Opportunity in the US

13.8.4. Encapsulated Cell Therapies Market for Oncological Disorders: Head and Neck Cancer, till 2030
13.8.4.1. MVX-ONCO-1 (MaxiVAX)
13.8.4.1.1. Target Patient Population
13.8.4.1.2. Sales Forecast
13.8.4.1.3. Geographical Distribution of Projected Opportunity
13.8.4.1.3.1. Projected Opportunity in EU5
13.8.4.1.3.2. Projected Opportunity in Rest of Europe
13.8.4.1.3.3. Projected Opportunity in the US

14.    CONCLUSION
14.1. Cell-based Pharmacological Interventions are Characterized by Diverse Challenges, Most of which can be Mitigated using Various Encapsulation Strategies
14.2. The Pipeline Features Several Mid and Late Stage Encapsulated Therapy Products, Majority of which are intended for the Treatment of Metabolic Disorders
14.3. The Fragmented Developer Landscape Includes a Mix of Small and Mid-Sized Players; at Present, North America and Europe are Major Hubs of Development Activity 
14.4. The Heightened Pace of Research in this Domain is Evident from the Rise in the Number of Patents Filed / Granted and the Clinical Studies Conducted in the Recent Years
14.5. Development Efforts in this Field have Drawn Significant Capital Investments from Private and Public Investors; this is Likely to Provide the Necessary Impetus to the Market’s Future Growth
14.6. Growth in Partnership Activity Reflects the Rising Interest of Industry Stakeholders; Most Agreements are Between Technology Providers and Cell Therapy Developers
14.7. Given the Increasing Number of Licensing Deals and the Expected Approval of Multiple Mid-Late Stage Candidates, the Market is Poised to Grow at a Significant Pace in the Coming Years

15.    EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Erytech Pharma
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Alexander Scheer, Chief Scientific Officer

15.3. Defymed
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Manuel Pires, Business Developer

15.4. Kadimastem
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Michel Revel, Chief Scientist and Galit Mazooz-Perlmuter, Business Development Manager

15.5. Aterelix
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Mick Mclean, Chief Executive Officer

15.6. Neurotech Pharmaceuticals
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Quinton Oswald, Former President and Chief Executive Officer

15.7. Seraxis
15.7.1. Company Snapshot
15.7.2. Interview Transcript: William L Rust, Founder and Chief Executive Officer

15.8. Beta-O2 Technologies
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Yuval Avni, Former Chief Executive Officer

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 

List of Figures

Figure 3.1 Key Steps Involved in Manufacturing Cell Therapies
Figure 3.2 Cell Therapy Supply Chain 
Figure 3.3 Encapsulation of Cells within Polymeric Membranes
Figure 3.4 Encapsulation of Active Drug Substances within Living Cells
Figure 3.5 Advantages of Encapsulated Cell Therapies and Encapsulation Technologies
Figure 3.6 Key Challenges Associated with Encapsulated Cell Therapies and Encapsulation Technologies
Figure 3.7 Potential Applications of Encapsulated Cell Therapies and Encapsulation Technologies
Figure 3.8 Growth Drivers and Road-blocks
Figure 4.1 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Year of Establishment
Figure 4.2 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Geographical Location
Figure 4.3 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Company Size (Employee Count)
Figure 4.4 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Type of Offering
Figure 4.5 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area
Figure 4.6 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Disease Indications
Figure 4.7 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Phase of Development
Figure 4.8 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area and Phase of Development
Figure 4.9 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Cells and Other Encapsulated Components
Figure 4.10 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Encapsulation Materials
Figure 4.11 Encapsulated Cell Therapies and Encapsulation Technologies: Grid Analysis
Figure 4.12 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Route of Administration
Figure 4.13 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Application Area
Figure 6.1 Living Cell Technologies: Revenues and Other Income, FY 2013 - FY 2018 (USD Million)
Figure 7.1 Patents Analysis: Distribution by Type
Figure 7.2 Patents Analysis: Cumulative Year-wise Trend, 2013-2018
Figure 7.3 Patents Analysis: Distribution by Geographical Location
Figure 7.4 Patents Analysis: Distribution by CPC Classifications (Top 20)
Figure 7.5 Patents Analysis: Emerging Focus Areas
Figure 7.6 Most Active Industry Players: Distribution by Number of Patents
Figure 7.7 Most Active Non-Industry Players: Distribution by Number of Patents
Figure 7.8 Patents Analysis: Benchmarking by Patent Characteristics
Figure 7.9 Patents Analysis: Benchmarking by Number of Patents Published Across Different Geographies
Figure 7.10 Patents Analysis: Benchmarking by Number of International Patents
Figure 7.11 Patents Analysis: Distribution by Patent Age, 2013-2018
Figure 7.12 Patents Analysis: Distribution by Geography and Publication Year, 2013-2018
Figure 7.13 Patents Analysis: Distribution by Relative Valuation
Figure 8.1. Clinical Trial Analysis: Distribution by Trial Status
Figure 8.2 Clinical Trial Analysis: Cumulative Distribution by Registration Year, Pre-2010-2018
Figure 8.3 Clinical Trial Analysis: Geographical Distribution of Trials
Figure 8.4 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.6 Clinical Trial Analysis: Distribution by Study Design
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.8 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.9 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.10 Clinical Trial Analysis: Popular Keywords
Figure 8.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 8.12 Popular Indications: Distribution by Number of Registered Trials across Key Therapeutic Areas
Figure 8.13 Clinical Trial Analysis: Benchmarking by Number of Registered Trials
Figure 8.14 Clinical Trial Analysis: Distribution of Clinical Endpoints by Trial Phase
Figure 9.1 Recent Partnerships: Cumulative Year-wise Trend, 2013-2018
Figure 9.2 Recent Partnerships: Distribution by Type of Partnership 
Figure 9.3 Recent Partnerships: Year-wise Trend by Type of Partnership
Figure 9.4 Recent Partnerships: Distribution by Therapeutic Area
Figure 9.5 Recent Partnerships: Popular Disease Indications
Figure 9.6 Recent Partnerships: Year-wise Trend by Therapeutic Area
Figure 9.7 Recent Partnerships: Popular Type of Cells and Other Encapsulated Components
Figure 9.8 Most Active Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Players: Regional Distribution by Number of Partnerships
Figure 9.10 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2013-2018
Figure 10.2 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2013-2018
Figure 10.3 Funding and Investments: Cumulative Year-wise Trend, 2013-2018
Figure 10.4 Funding and Investments: Cumulative Amount Invested by Year, 2013-2018 (USD Million)
Figure 10.5 Funding and Investments: Distribution by Type of Funding
Figure 10.6 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 10.7 Popular Indications: Distribution by Number of Funding Instances
Figure 10.8 Popular Indications: Distribution by Amount Invested (USD Million)
Figure 10.9 Funding Instances: Year-wise Trend of Amount Invested across Different Indications, 2013-2018 (USD Million)
Figure 10.10 Funding and Investments: Popular Type of Cells and Other Encapsulated Components by Amount Invested (USD Million)
Figure 10.11 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 10.12 Most Active Investors: Distribution by Number of Instances
Figure 10.13 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 10.14 Funding and Investment Summary
Figure 11.1 Academic Grant Analysis Cumulative Trend by Year of Award, 2013-2018
Figure 11.2 Academic Grant Analysis: Emerging Focus Areas
Figure 11.3 Academic Grant Analysis: Distribution by Support Period
Figure 11.4 Academic Grant Analysis: Distribution by Grant Type
Figure 11.5 Academic Grant Analysis: Year-wise Trend by Leading Grant Type
Figure 11.6 Academic Grant Analysis: Capital Amount Awarded by Grant Type
Figure 11.7 Academic Grant Analysis: Distribution by Responsible Study Section
Figure 11.8 Academic Grant Analysis: Distribution by Therapeutic Area
Figure 11.9 Popular Indications: Distribution by Number of Grants Awarded
Figure 11.10 Academic Grant Analysis: Year-wise Trend by Key Therapeutic Areas
Figure 11.11 Academic Grant Analysis: Benchmarking by Number of Grants Awarded across Key Therapeutic Areas
Figure 11.12 Academic Grant Analysis: Popular Types of Cells and Other Encapsulated Components
Figure 11.13 Academic Grant Analysis: Popular Types of Encapsulation Materials
Figure 11.14 Most Active Funding Institutes: Distribution by Number of Grants Awarded
Figure 11.15 Most Active Recipient Organizations: Distribution by Number of Grants Received
Figure 11.16 Academic Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Technology Licensing Deal: Payment Structure
Figure 13.3 Cell Encapsulation Technologies: Overall Market, 2019-2030 (USD Million)
Figure 13.4 Cell Encapsulation Technologies Market by Upfront Payments, 2019-2030 (USD Million)
Figure 13.5 Cell Encapsulation Technologies Market by Milestone Payments, 2019-2030 (USD Million)
Figure 13.6 Overall Encapsulated Cell Therapies Market, till 2030 (USD Million)
Figure 13.7 Encapsulated Cell Therapies Market for Eye Disorders, till 2030 (USD Million)
Figure 13.8 Encapsulated Cell Therapies Market for Metabolic Disorders, till 2030 (USD Million)
Figure 13.9 Encapsulated Cell Therapies Market for Neurological Disorders, till 2030 (USD Million)
Figure 13.10 Encapsulated Cell Therapies Market for Oncological Disorders, till 2030 (USD Million)
Figure 13.11 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, till 2030 (USD Million)
Figure 13.12 Encapsulated Cell Therapies Market for Cellulose Hydrogels, till 2030 (USD Million)
Figure 13.13 Encapsulated Cell Therapies Market for Medical-grade Plastics, till 2030 (USD Million)
Figure 13.14 Encapsulated Cell Therapies Market for Red Blood Cells, till 2030 (USD Million)
Figure 13.15 Encapsulated Cell Therapies Market in North America, till 2030 (USD Million)
Figure 13.16 Encapsulated Cell Therapies Market in Europe, till 2030 (USD Million)
Figure 13.17 Encapsulated Cell Therapies Market in Asia-Pacific, till 2030 (USD Million)
Figure 13.18 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.19 NT-501: Target Patient Population of Macular Telangiectasia
Figure 13.20 NT-501: Sales Forecast for Macular Telangiectasia, till 2030 (USD Million)
Figure 13.21 NT-501: Projected Opportunity for Macular Telangiectasia in the US, till 2030 (USD Million)
Figure 13.22 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, till 2030 (USD Million)
Figure 13.23 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, till 2030 (USD Million)
Figure 13.24 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, till 2030 (USD Million)
Figure 13.25 NT-501: Target Patient Population of Glaucoma
Figure 13.26 NT-501: Sales Forecast for Glaucoma, till 2030 (USD Million)
Figure 13.27 NT-501: Projected Opportunity for Glaucoma in the US, till 2030 (USD Million)
Figure 13.28 NT-501: Projected Opportunity for Glaucoma in EU5, till 2030 (USD Million)
Figure 13.29 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, till 2030 (USD Million)
Figure 13.30 NT-501: Projected Opportunity for Glaucoma in Australia, till 2030 (USD Million)
Figure 13.31 NT-501: Target Patient Population of Retinitis Pigmentosa
Figure 13.32 NT-501: Sales Forecast for Retinitis Pigmentosa, till 2030 (USD Million)
Figure 13.33 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, till 2030 (USD Million)
Figure 13.34 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, till 2030 (USD Million)
Figure 13.35 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, till 2030 (USD Million)
Figure 13.36 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, till 2030 (USD Million)
Figure 13.37 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.38 DIABECELL: Target Patient Population of Type 1 Diabetes
Figure 13.39 DIABECELL: Sales Forecast for Type 1 Diabetes, till 2030 (USD Million)
Figure 13.40 DIABECELL: Projected Opportunity for Type 1 Diabetes in the US, till 2030 (USD Million)
Figure 13.41 DIABECELL: Projected Opportunity for Type 1 Diabetes in Japan, till 2030 (USD Million)
Figure 13.42 DIABECELL: Projected Opportunity for Type 1 Diabetes in EU5, till 2030 (USD Million)
Figure 13.43 DIABECELL: Projected Opportunity for Type 1 Diabetes in Rest of Europe, till 2030 (USD Million)
Figure 13.44 DIABECELL: Projected Opportunity for Type 1 Diabetes in Australia, till 2030 (USD Million)
Figure 13.45 DIABECELL: Projected Opportunity for Type 1 Diabetes in New Zealand, till 2030 (USD Million)
Figure 13.46 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.47 EryDex System: Target Patient Population of Ataxia Telangiectasia
Figure 13.48 EryDex System: Sales Forecast for Ataxia Telangiectasia, till 2030 (USD Million)
Figure 13.49 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, till 2030 (USD Million)
Figure 13.50 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, till 2030 (USD Million)
Figure 13.51 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, till 2030 (USD Million)
Figure 13.52 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, till 2030 (USD Million)
Figure 13.53 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, till 2030 (USD Million)
Figure 13.54 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, till 2030 (USD Million)
Figure 13.55 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, till 2030 (USD Million)
Figure 13.56 NTCELL: Target Patient Population of Parkinson’s Disease
Figure 13.57 NTCELL: Sales Forecast for Parkinson’s Disease, till 2030 (USD Million)
Figure 13.58 NTCELL: Projected Opportunity for Parkinson’s Disease in New Zealand, till 2030 (USD Million)
Figure 13.59 NTCELL: Projected Opportunity for Parkinson’s Disease in the US, till 2030 (USD Million)
Figure 13.60 NTCELL: Projected Opportunity for Parkinson’s Disease in Australia, till 2030 (USD Million)
Figure 13.61 NTCELL: Projected Opportunity for Parkinson’s Disease in EU5, till 2030 (USD Million)
Figure 13.62 NTCELL: Projected Opportunity for Parkinson’s Disease in Rest of Europe, till 2030 (USD Million)
Figure 13.63 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, till 2030 (USD Million)
Figure 13.64 GRASPA: Target Patient Population of Metastatic Pancreatic Cancer
Figure 13.65 GRASPA: Sales Forecast for Metastatic Pancreatic Cancer, till 2030 (USD Million)
Figure 13.66 GRASPA: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, till 2030 (USD Million)
Figure 13.67 GRASPA: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, till 2030 (USD Million)
Figure 13.68 GRASPA: Projected Opportunity for Metastatic Pancreatic Cancer in the US, till 2030 (USD Million)
Figure 13.69 Cell-in-a-Box: Target Patient Population of Non-Metastatic Pancreatic Cancer
Figure 13.70 Cell-in-a-Box: Sales Forecast for Non-Metastatic Pancreatic Cancer, till 2030 (USD Million)
Figure 13.71 Cell-in-a-Box: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, till 2030 (USD Million)
Figure 13.72 Cell-in-a-Box: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, till 2030 (USD Million)
Figure 13.73 Cell-in-a-Box: Projected Opportunity for Non-Metastatic Pancreatic Cancer in rest of Europe, till 2030 (USD Million)
Figure 13.74 GRASPA: Target Patient Population of Triple Negative Breast Cancer
Figure 13.75 GRASPA: Sales Forecast for Triple Negative Breast Cancer, till 2030 (USD Million)
Figure 13.76 GRASPA: Projected Opportunity for Triple Negative Breast Cancer in EU5, till 2030 (USD Million)
Figure 13.77 GRASPA: Projected Opportunity for Triple Negative Breast Cancer in rest of Europe, till 2030 (USD Million)
Figure 13.78 GRASPA: Projected Opportunity for Triple Negative Breast Cancer in the US, till 2030 (USD Million)
Figure 13.79 MaxiVAX: Target Patient Population of Head and Neck Cancer
Figure 13.80 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, till 2030 (USD Million)
Figure 13.81 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, till 2030 (USD Million)
Figure 13.82 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, till 2030 (USD Million)
Figure 13.83 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, till 2030 (USD Million)

List of Tables

Table 3.1 Applications of Cell-based Therapies  
Table 3.2 Types of Encapsulation Materials
Table 4.1 Encapsulated Cell Therapies and Encapsulation Technologies: Developer Overview
Table 4.2 Encapsulated Cell Therapies and Encapsulation Technologies: Development Pipeline
Table 4.3 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area and Phase of Development
Table 4.4 Encapsulated Cell Therapies and Encapsulation Technologies: Additional Information 
Table 4.5 Encapsulated Cell Therapies and Encapsulation Technologies: Initiatives of Big Pharmaceutical Players
Table 5.1 Beta-O2 Technologies: Key Highlights
Table 5.2 Beta-O2 Technologies: Funding Instances
Table 5.3 Beta-O2 Technologies: Key Characteristics of βAir Bio-artificial Pancreas
Table 5.4 Beta-O2 Technologies: Recent Developments and Future Outlook
Table 5.5 Diatranz Otsuka: Key Highlights
Table 5.6 Diatranz Otsuka: Key Characteristics of DIABECELL®
Table 5.7 Diatranz Otsuka: Recent Developments and Future Outlook
Table 5.8 Sernova: Key Highlights
Table 5.9 Sernova: Funding Instances
Table 5.10 Sernova: Key Characteristics of Cell Pouch System™
Table 5.11 Sernova: Recent Developments and Future Outlook
Table 5.12 ViaCyte: Key Highlights
Table 5.13 ViaCyte: Funding Instances
Table 5.14 ViaCyte: Key Characteristics of PEC-Direct™ and PEC-Encap™
T able 5.15 ViaCyte: Recent Developments and Future Outlook
Table 5.16 Company 1: Key Highlights
Table 5.17 Company 2: Key Highlights
Table 5.18 Betalin Therapeutics: Key Highlights
Table 5.19 Company 4: Key Highlights
Table 5.20 Defymed: Key Highlights
Table 5.21 Company 6: Key Highlights
Table 5.22 Kadimastem: Key Highlights
Table 5.23 Company 8: Key Highlights
Table 5.24 Company 9: Key Highlights
Table 5.25 Company 10: Key Highlights
Table 5.26 Seraxis: Key Highlights
Table 5.27 Company 12: Key Highlights
Table 6.1 Azellon Cell Therapeutics: Key Highlights
Table 6.2 Azellon Cell Therapeutics: Key Characteristics of Cell Bandage
Table 6.3 Azellon Cell Therapeutics: Recent Developments and Future Outlook
Table 6.4 EryDel: Key Highlights
Table 6.5 EryDel: Funding Instances
Table 6.6 EryDel: Key Characteristics of EryDex System
Table 6.7 EryDel: Recent Developments and Future Outlook
Table 6.8 Erytech Pharma: Key Highlights
Table 6.9 Erytech Pharma: Funding Instances
Table 6.10 Erytech Pharma: Key Characteristics of GRASPA®
Table 6.11 Erytech Pharma: Recent Developments and Future Outlook
Table 6.12 Gloriana Therapeutics: Key Highlights
Table 6.13 Gloriana Therapeutics: Key Characteristics of EC-NGF
Table 6.14 Gloriana Therapeutics: Recent Developments and Future Outlook
Table 6.15 Living Cell Technologies: Key Highlights
Table 6.16 Living Cell Technologies: Key Characteristics of NTCELL®
Table 6.17 Living Cell Technologies: Recent Developments and Future Outlook
Table 6.18 MaxiVAX: Key Highlights
Table 6.19 MaxiVAX: Key Characteristics of MVX-ONCO-1
Table 6.20 MaxiVAX: Recent Developments and Future Outlook
Table 6.21 Neurotech Pharmaceuticals: Key Highlights
Table 6.22 Neurotech Pharmaceuticals: Key Characteristics of NT-501
Table 6.23 Neurotech Pharmaceuticals: Recent Developments and Future Outlook
Table 6.24 PharmaCyte Biotech: Key Highlights
Table 6.25 PharmaCyte Biotech: Funding Instances
Table 6.26 PharmaCyte Biotech: Key Characteristics of Cell-in-a-Box®
Table 6.27 PharmaCyte Biotech: Recent Developments and Future Outlook
Table 6.28 Company 1: Key Highlights
Table 6.29 Sernova: Key Highlights
Table 6.30 Company 3: Key Highlights
Table 7.1 Patents: CPC Classification Symbol Definitions
Table 7.2 Patents: Most Popular CPC Classification Symbols
Table 7.3 Patents: List of Top CPC Classifications
Table 7.4 Encapsulated Cell Therapies and Encapsulation Technologies: Summary of Patent Benchmarking Analysis
Table 7.5 Encapsulated Cell Therapies and Encapsulation Technologies: Categorizations based on Weighted Valuation Scores 
Table 7.6 Leading Patents: Distribution by Relative Valuation
Table 7.7 Leading Patents: Distribution by Number of Citations
Table 8.1 Encapsulated Cell Therapies and Encapsulation Technologies: List of Clinical Trials
Table 8.2 Clinical Trials: Most Popular Clinical Endpoints by Phase of Development
Table 9.1  Encapsulated Cell Therapies and Encapsulation Technologies: List of Partnerships, 2013-2018
Table 9.2  Most Active Players: Distribution by Number of Partnerships
Table 10.1 Encapsulated Cell Therapies and Encapsulation Technologies: List of Funding Instances, 2013-2018
Table 10.2 Encapsulated Cell Therapies and Encapsulation Technologies: Summary of Investments
Table 11.1 Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants, 2013-2018
Table 11.2 Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants (Additional Information), 2013-2018
Table 12.1 Opportunities in North America: Most Likely Partners for Cell Therapy Development
Table 12.2 Opportunities in North America: Likely Partners for Cell Therapy Development
Table 12.3 Opportunities in North America: Less Likely Partners for Cell Therapy Development
Table 12.4 Opportunities in Europe: Most Likely Partners for Cell Therapy Development
Table 12.5 Opportunities in Europe: Likely Partners for Cell Therapy Development
Table 12.6 Opportunities in Europe: Less Likely Partners for Cell Therapy Development
Table 12.7 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners for Cell Therapy Development
Table 12.8 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Cell Therapy Development
Table 12.9 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners for Cell Therapy Development
Table 12.10 Opportunities in North America: Most Likely Partners for Cell Therapy Manufacturing
Table 12.11 Opportunities in North America: Likely Partners for Cell Therapy Manufacturing
Table 12.12 Opportunities in North America: Less Likely Partners for Cell Therapy Manufacturing
Table 12.13 Opportunities in Europe: Most Likely Partners for Cell Therapy Manufacturing
Table 12.14 Opportunities in Europe: Likely Partners for Cell Therapy Manufacturing
Table 12.15 Opportunities in Europe: Less Likely Partners for Cell Therapy Manufacturing
Table 12.16 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners for Cell Therapy Manufacturing
Table 12.17 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Cell Therapy Manufacturing
Table 12.18 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners for Cell Therapy Manufacturing
Table 13.1 Technology Licensing Deal: Tranches of Milestone Payments
Table 13.2 Cell Encapsulation Technologies: Average Upfront Payments and Average Milestone Payments, 2012-2018 (USD Million)
Table 13.3 List of Forecasted Encapsulated Cell Therapies
Table 13.4 Categorization of Likely Prices Considered for Encapsulated Cell Therapies
Table 13.5 Categorization of Expected Adoption Rates Considered for Encapsulated Cell Therapies
Table 15.1 Erytech Pharma: Key Highlights
Table 15.2 Defymed: Key Highlights
Table 15.3 Kadimastem: Key Highlights
Table 15.4 Aterelix: Key Highlights
Table 15.5 Neurotech Pharmaceuticals: Key Highlights
Table 15.6 Seraxis: Key Highlights
Table 15.7 Beta-O2 Technologies: Key Highlights
Table 16.1 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Year of Establishment
Table 16.2 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Geographical Location
Table 16.3 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Company Size (Employee Count)
Table 16.4 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution of Industry Players by Type of Offering
Table 16.5 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area
Table 16.6 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Disease Indications
Table 16.7 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Phase of Development
Table 16.8 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Therapeutic Area and Phase of Development
Table 16.9 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Cells and Other Encapsulated Components
Table 16.10 Encapsulated Cell Therapies and Encapsulation Technologies: Popular Type of Encapsulation Materials
Table 16.11 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Route of Administration
Table 16.12 Encapsulated Cell Therapies and Encapsulation Technologies: Distribution by Application Area
Table 16.13 Living Cell Technologies: Revenues and Other Income, FY 2013 - FY 2018 (USD Million)
Table 16.14 Patents Analysis: Distribution by Type
Table 16.15 Patents Analysis: Cumulative Year-wise Trend, 2013-2018
Table 16.16 Patents Analysis: Distribution by Geographical Location
Table 16.17 Patents Analysis: Distribution by CPC Classifications (Top 20)
Table 16.18 Most Active Industry Players: Distribution by Number of Patents
Table 16.19 Most Active Non-Industry Players: Distribution by Number of Patents
Table 16.20 Patents Analysis: Benchmarking by Patent Characteristics
Table 16.21 Patents Analysis: Benchmarking by Number of Patents Published Across Different Geographies
Table 16.22 Patents Analysis: Benchmarking by Number of International Patents
Table 16.23 Patents Analysis: Distribution by Patent Age, 2013-2018
Table 16.24 Patents Analysis: Distribution by Geography and Publication Year, 2013-2018
Table 16.25 Patents Analysis: Distribution by Relative Valuation
Table 16.26 Clinical Trial Analysis: Distribution by Trial Status
Table 16.27 Clinical Trial Analysis: Cumulative Distribution by Registration Year, Pre-2010-2018
Table 16.28 Clinical Trial Analysis: Geographical Distribution of Trials
Table 16.29 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 16.30 Clinical Trial Analysis: Distribution by Trial Phase
Table 16.31 Clinical Trial Analysis: Distribution by Study Design
Table 16.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 16.33 Most Active Industry Players: Distribution by Number of Registered Trials
Table 16.34 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 16.35 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 16.36 Popular Indications: Distribution by Number of Registered Trials across Key Therapeutic Areas
Table 16.37 Clinical Trial Analysis: Benchmarking by Number of Registered Trials
Table 16.38 Clinical Trial Analysis: Distribution of Clinical Endpoints by Trial Phase
Table 16.39 Recent Partnerships: Cumulative Year-wise Trend, 2013-2018
Table 16.40 Recent Partnerships: Distribution by Type of Partnership 
Table 16.41 Recent Partnerships: Year-wise Trend by Type of Partnership
Table 16.42 Recent Partnerships: Distribution by Therapeutic Area
Table 16.43 Recent Partnerships: Popular Disease Indications
Table 16.44 Recent Partnerships: Year-wise Trend by Therapeutic Area
Table 16.45 Recent Partnerships: Popular Type of Cells and Other Encapsulated Components
Table 16.46 Most Active Players: Distribution by Number of Partnerships
Table 16.47 Most Active Players: Regional Distribution by Number of Partnerships
Table 16.48 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 16.49 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2013-2018
Table 16.50 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2013-2018
Table 16.51 Funding and Investments: Cumulative Year-wise Trend, 2013-2018
Table 16.52 Funding and Investments: Cumulative Amount Invested by Year, 2013-2018 (USD Million)
Table 16.53 Funding and Investments: Distribution by Type of Funding
Table 16.54 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 16.55 Popular Indications: Distribution by Number of Funding Instances
Table 16.56 Popular Indications: Distribution by Amount Invested (USD Million)
Table 16.57 Funding Instances: Year-wise Trend of Amount Invested across Different Indications, 2013-2018 (USD Million)
Table 16.58 Funding and Investments: Popular Type of Cells and Other Encapsulated Components by Amount Invested (USD Million)
Table 16.59 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 16.60 Most Active Investors: Distribution by Number of Instances
Table 16.61 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 16.62 Academic Grant Analysis Cumulative Trend by Year of Award, 2013-2018
Table 16.63 Academic Grant Analysis: Distribution by Support Period
Table 16.64 Academic Grant Analysis: Distribution by Grant Type
Table 16.65 Academic Grant Analysis: Year-wise Trend by Leading Grant Type
Table 16.66 Academic Grant Analysis: Capital Amount Awarded by Grant Type
Table 16.67  Academic Grant Analysis: Distribution by Responsible Study Section
Table 16.68  Academic Grant Analysis: Distribution by Therapeutic Area
Table 16.69  Popular Indications: Distribution by Number of Grants Awarded
Table 16.70  Academic Grant Analysis: Year-wise Trend by Key Therapeutic Areas
Table 16.71  Academic Grant Analysis: Benchmarking by Number of Grants Awarded across Key Therapeutic Areas
Table 16.72  Academic Grant Analysis: Popular Types of Cells and Other Encapsulated Components
Table 16.73  Academic Grant Analysis: Popular Types of Encapsulation Materials
Table 16.74  Most Active Funding Institutes: Distribution by Number of Grants Awarded
Table 16.75  Most Active Recipient Organizations: Distribution by Number of Grants Received
Table 16.76  Academic Grant Analysis: Geographical Distribution of Recipient Organizations
Table 16.77 Overall Cell Encapsulation Technologies Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.78 Overall Cell Encapsulation Technologies Market, Base Scenario, 2019-2030 (USD Million)
Table 16.79 Overall Cell Encapsulation Technologies Market, Optimistic Scenario, 2019-2030 (USD Million)
Table 16.80 Cell Encapsulation Technologies Market by Upfront Payments, Conservative Scenario, till 2030 (USD Million)
Table 16.81 Cell Encapsulation Technologies Market by Upfront Payments, Base Scenario, till 2030 (USD Million)
Table 16.82 Cell Encapsulation Technologies Market by Upfront Payments, Optimistic Scenario, till 2030 (USD Million)
Table 16.83 Cell Encapsulation Technologies Market by Milestone Payments, Conservative Scenario, till 2030 (USD Million)
Table 16.84 Cell Encapsulation Technologies Market by Milestone Payments, Base Scenario, till 2030 (USD Million)
Table 16.85 Cell Encapsulation Technologies Market by Milestone Payments, Optimistic Scenario, till 2030 (USD Million)
Table 16.86 Overall Encapsulated Cell Therapies Market, Conservative Scenario, till 2030 (USD Million)
Table 16.87 Overall Encapsulated Cell Therapies Market, Base Scenario, till 2030 (USD Million)
Table 16.88 Overall Encapsulated Cell Therapies Market, Optimistic Scenario, till 2030 (USD Million)
Table 16.89 Encapsulated Cell Therapies Market for Eye Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.90 Encapsulated Cell Therapies Market for Eye Disorders, Base Scenario, till 2030 (USD Million)
Table 16.91 Encapsulated Cell Therapies Market for Eye Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.92 Encapsulated Cell Therapies Market for Metabolic Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.93 Encapsulated Cell Therapies Market for Metabolic Disorders, Base Scenario, till 2030 (USD Million)
Table 16.94 Encapsulated Cell Therapies Market for Metabolic Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.95 Encapsulated Cell Therapies Market for Neurological Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.96 Encapsulated Cell Therapies Market for Neurological Disorders, Base Scenario, till 2030 (USD Million)
Table 16.97 Encapsulated Cell Therapies Market for Neurological Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.98 Encapsulated Cell Therapies Market for Oncological Disorders, Conservative Scenario, till 2030 (USD Million)
Table 16.99 Encapsulated Cell Therapies Market for Oncological Disorders, Base Scenario, till 2030 (USD Million)
Table 16.100 Encapsulated Cell Therapies Market for Oncological Disorders, Optimistic Scenario, till 2030 (USD Million)
Table 16.101 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, Conservative Scenario, till 2030 (USD Million)
Table 16.102 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, Base Scenario, till 2030 (USD Million)
Table 16.103 Encapsulated Cell Therapies Market for Alginate-based Microcapsules, Optimistic Scenario, till 2030 (USD Million)
Table 16.104 Encapsulated Cell Therapies Market for Cellulose Hydrogels, Conservative Scenario, till 2030 (USD Million)
Table 16.105 Encapsulated Cell Therapies Market for Cellulose Hydrogels, Base Scenario, till 2030 (USD Million)
Table 16.106 Encapsulated Cell Therapies Market for Cellulose Hydrogels, Optimistic Scenario, till 2030 (USD Million)
Table 16.107 Encapsulated Cell Therapies Market for Medical-grade Plastics, Conservative Scenario, till 2030 (USD Million)
Table 16.108 Encapsulated Cell Therapies Market for Medical-grade Plastics, Base Scenario, till 2030 (USD Million)
Table 16.109 Encapsulated Cell Therapies Market for Medical-grade Plastics, Optimistic Scenario, till 2030 (USD Million)
Table 16.110 Encapsulated Cell Therapies Market for Red Blood Cells, Conservative Scenario, till 2030 (USD Million)
Table 16.111 Encapsulated Cell Therapies Market for Red Blood Cells, Base Scenario, till 2030 (USD Million)
Table 16.112 Encapsulated Cell Therapies Market for Red Blood Cells, Optimistic Scenario, till 2030 (USD Million)
Table 16.113 Encapsulated Cell Therapies Market in North America, Conservative Scenario, till 2030 (USD Million)
Table 16.114 Encapsulated Cell Therapies Market in North America, Base Scenario, till 2030 (USD Million)
Table 16.115 Encapsulated Cell Therapies Market in North America, Optimistic Scenario, till 2030 (USD Million)
Table 16.116 Encapsulated Cell Therapies Market in Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.117 Encapsulated Cell Therapies Market in Europe, Base Scenario, till 2030 (USD Million)
Table 16.118 Encapsulated Cell Therapies Market in Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.119 Encapsulated Cell Therapies Market in Asia-Pacific, Conservative Scenario, till 2030 (USD Million)
Table 16.120 Encapsulated Cell Therapies Market in Asia-Pacific, Base Scenario, till 2030 (USD Million)
Table 16.121 Encapsulated Cell Therapies Market in Asia-Pacific, Optimistic Scenario, till 2030 (USD Million)
Table 16.122 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, Conservative Scenario, till 2030 (USD Million)
Table 16.123 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.124 Encapsulated Cell Therapies Market for Eye Disorders: Distribution by Indication, Optimistic Scenario, till 2030 (USD Million)
Table 16.125 NT-501: Sales Forecast for Macular Telangiectasia, Conservative Scenario, till 2030 (USD Million)
Table 16.126 NT-501: Sales Forecast for Macular Telangiectasia, Base Scenario, till 2030 (USD Million)
Table 16.127 NT-501: Sales Forecast for Macular Telangiectasia, Optimistic Scenario, till 2030 (USD Million)
Table 16.128 NT-501: Projected Opportunity for Macular Telangiectasia in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.129 NT-501: Projected Opportunity for Macular Telangiectasia in the US, Base Scenario, till 2030 (USD Million)
Table 16.130 NT-501: Projected Opportunity for Macular Telangiectasia in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.131 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.132 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, Base Scenario, till 2030 (USD Million)
Table 16.133 NT-501: Projected Opportunity for Macular Telangiectasia in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.134 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.135 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.136 NT-501: Projected Opportunity for Macular Telangiectasia in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.137 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.138 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, Base Scenario, till 2030 (USD Million)
Table 16.139 NT-501: Projected Opportunity for Macular Telangiectasia in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.140 NT-501: Sales Forecast for Glaucoma, Conservative Scenario, till 2030 (USD Million)
Table 16.141 NT-501: Sales Forecast for Glaucoma, Base Scenario, till 2030 (USD Million)
Table 16.142 NT-501: Sales Forecast for Glaucoma, Optimistic Scenario, till 2030 (USD Million)
Table 16.143 NT-501: Projected Opportunity for Glaucoma in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.144 NT-501: Projected Opportunity for Glaucoma in the US, Base Scenario, till 2030 (USD Million)
Table 16.145 NT-501: Projected Opportunity for Glaucoma in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.146 NT-501: Projected Opportunity for Glaucoma in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.147 NT-501: Projected Opportunity for Glaucoma in EU5, Base Scenario, till 2030 (USD Million)
Table 16.148 NT-501: Projected Opportunity for Glaucoma in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.149 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.150 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.151 NT-501: Projected Opportunity for Glaucoma in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.152 NT-501: Projected Opportunity for Glaucoma in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.153 NT-501: Projected Opportunity for Glaucoma in Australia, Base Scenario, till 2030 (USD Million)
Table 16.154 NT-501: Projected Opportunity for Glaucoma in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.155 NT-501: Sales Forecast for Retinitis Pigmentosa, Conservative Scenario, till 2030 (USD Million)
Table 16.156 NT-501: Sales Forecast for Retinitis Pigmentosa, Base Scenario, till 2030 (USD Million)
Table 16.157 NT-501: Sales Forecast for Retinitis Pigmentosa, Optimistic Scenario, till 2030 (USD Million)
Table 16.158 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.159 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, Base Scenario, till 2030 (USD Million)
Table 16.160 NT-501: Projected Opportunity for Retinitis Pigmentosa in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.161 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.162 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, Base Scenario, till 2030 (USD Million)
Table 16.163 NT-501: Projected Opportunity for Retinitis Pigmentosa in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.164 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.165 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.166 NT-501: Projected Opportunity for Retinitis Pigmentosa in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.167 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.168 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, Base Scenario, till 2030 (USD Million)
Table 16.169 NT-501: Projected Opportunity for Retinitis Pigmentosa in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.170 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Conservative Scenario, till 2030(USD Million)
Table 16.171 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.172 Encapsulated Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Optimistic Scenario, till 2030 (USD Million)
Table 16.173 DIABECELL®®: Sales Forecast for Type 1 diabetes, Conservative Scenario, till 2030 (USD Million)
Table 16.174 DIABECELL®®: Sales Forecast for Type 1 diabetes, Base Scenario, till 2030 (USD Million)
Table 16.175 DIABECELL®®: Sales Forecast for Type 1 diabetes, Optimistic Scenario, till 2030 (USD Million)
Table 16.176 DIABECELL®: Projected Opportunity for Type 1 Diabetes in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.177 DIABECELL®: Projected Opportunity for Type 1 Diabetes in the US, Base Scenario, till 2030 (USD Million)
Table 16.178 DIABECELL®: Projected Opportunity for Type 1 Diabetes in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.179 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Japan, Conservative Scenario, till 2030 (USD Million)
Table 16.180 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Japan, Base Scenario, till 2030 (USD Million)
Table 16.181 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Japan, Optimistic Scenario, till 2030 (USD Million)
Table 16.182 DIABECELL®: Projected Opportunity for Type 1 Diabetes in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.183 DIABECELL®: Projected Opportunity for Type 1 Diabetes in EU5, Base Scenario, till 2030 (USD Million)
Table 16.184 DIABECELL®: Projected Opportunity for Type 1 Diabetes in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.185 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.186 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.187 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.188 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.189 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Australia, Base Scenario, till 2030 (USD Million)
Table 16.190 DIABECELL®: Projected Opportunity for Type 1 Diabetes in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.191 DIABECELL®: Projected Opportunity for Type 1 Diabetes in New Zealand, Conservative Scenario, till 2030 (USD Million)
Table 16.192 DIABECELL®: Projected Opportunity for Type 1 Diabetes in New Zealand, Base Scenario, till 2030 (USD Million)
Table 16.193 DIABECELL®: Projected Opportunity for Type 1 Diabetes in New Zealand, Optimistic Scenario, till 2030 (USD Million)
Table 16.194 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, Conservative Scenario, till 2030 (USD Million)
Table 16.195 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.196 Encapsulated Cell Therapies Market for Neurological Disorders: Distribution by Indication, Optimistic Scenario, till 2030 (USD Million)
Table 16.197 EryDex System: Sales Forecast for Ataxia Telangiectasia, Conservative Scenario, till 2030 (USD Million)
Table 16.198 EryDex System: Sales Forecast for Ataxia Telangiectasia, Base Scenario, till 2030 (USD Million)
Table 16.199 EryDex System: Sales Forecast for Ataxia Telangiectasia, Optimistic Scenario, till 2030 (USD Million)
Table 16.200 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.201 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, Base Scenario, till 2030 (USD Million)
Table 16.202 EryDex System: Projected Opportunity for Ataxia Telangiectasia in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.203 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.204 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.205 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.206 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.207 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, Base Scenario, till 2030 (USD Million)
Table 16.208 EryDex System: Projected Opportunity for Ataxia Telangiectasia in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.209 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.210 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, Base Scenario, till 2030 (USD Million)
Table 16.211 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.212 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, Conservative Scenario, till 2030 (USD Million)
Table 16.213 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, Base Scenario, till 2030 (USD Million)
Table 16.214 EryDex System: Projected Opportunity for Ataxia Telangiectasia in India, Optimistic Scenario, till 2030 (USD Million)
Table 16.215 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, Conservative Scenario, till 2030 (USD Million)
Table 16.216 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, Base Scenario, till 2030 (USD Million)
Table 16.217 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Israel, Optimistic Scenario, till 2030 (USD Million)
Table 16.218 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, Conservative Scenario, till 2030 (USD Million)
Table 16.219 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, Base Scenario, till 2030 (USD Million)
Table 16.220 EryDex System: Projected Opportunity for Ataxia Telangiectasia in Tunisia, Optimistic Scenario, till 2030 (USD Million)
Table 16.221 NTCELL®®: Sales Forecast for Parkinson’s Disease, Conservative Scenario, till 2030 (USD Million)
Table 16.222 NTCELL®: Sales Forecast for Parkinson’s Disease, Base Scenario, till 2030 (USD Million)
Table 16.223 NTCELL®: Sales Forecast for Parkinson’s Disease, Optimistic Scenario, till 2030 (USD Million)
Table 16.224 NTCELL®: Projected Opportunity for Parkinson’s Disease in New Zealand, Conservative Scenario, till 2030 (USD Million)
Table 16.225 NTCELL®: Projected Opportunity for Parkinson’s Disease in New Zealand, Base Scenario, till 2030 (USD Million)
Table 16.226 NTCELL®: Projected Opportunity for Parkinson’s Disease in New Zealand, Optimistic Scenario, till 2030 (USD Million)
Table 16.227 NTCELL®: Projected Opportunity for Parkinson’s Disease in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.228 NTCELL®: Projected Opportunity for Parkinson’s Disease in the US, Base Scenario, till 2030 (USD Million)
Table 16.229 NTCELL®: Projected Opportunity for Parkinson’s Disease in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.230 NTCELL®: Projected Opportunity for Parkinson’s Disease in Australia, Conservative Scenario, till 2030 (USD Million)
Table 16.231 NTCELL®: Projected Opportunity for Parkinson’s Disease in Australia, Base Scenario, till 2030 (USD Million)
Table 16.232 NTCELL®: Projected Opportunity for Parkinson’s Disease in Australia, Optimistic Scenario, till 2030 (USD Million)
Table 16.233 NTCELL®: Projected Opportunity for Parkinson’s Disease in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.234 NTCELL®: Projected Opportunity for Parkinson’s Disease in EU5, Base Scenario, till 2030 (USD Million)
Table 16.235 NTCELL®: Projected Opportunity for Parkinson’s Disease in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.236 NTCELL®: Projected Opportunity for Parkinson’s Disease in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.237 NTCELL®: Projected Opportunity for Parkinson’s Disease in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.238 NTCELL®: Projected Opportunity for Parkinson’s Disease in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.239 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, Conservative Scenario, till 2030 (USD Million)
Table 16.240 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, Base Scenario, till 2030 (USD Million)
Table 16.241 Encapsulated Cell Therapies Market for Oncological Disorders: Distribution by Indication, Optimistic Scenario, till 2030(USD Million)
Table 16.242 GRASPA®®: Sales Forecast for Metastatic Pancreatic Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.243 GRASPA®: Sales Forecast for Metastatic Pancreatic Cancer, Base Scenario, till 2030 (USD Million)
Table 16.244 GRASPA®: Sales Forecast for Metastatic Pancreatic Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.245 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.246 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.247 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.248 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.249 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.250 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.251 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.252 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.253 GRASPA®: Projected Opportunity for Metastatic Pancreatic Cancer in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.254 Cell-in-a-Box®®: Sales Forecast for Non-Metastatic Pancreatic Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.255 Cell-in-a-Box®: Sales Forecast for Non-Metastatic Pancreatic Cancer, Base Scenario, till 2030 (USD Million)
Table 16.256 Cell-in-a-Box®: Sales Forecast for Non-Metastatic Pancreatic Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.257 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.258 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.259 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.260 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.261 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.262 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.263 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in Rest of Europe, Conservative Scenario, till2030 (USD Million)
Table 16.264 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.265 Cell-in-a-Box®: Projected Opportunity for Non-Metastatic Pancreatic Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.266 GRASPA®: Sales Forecast for Triple Negative Breast Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.267 GRASPA®: Sales Forecast for Triple Negative Breast Cancer, Base Scenario, till 2030 (USD Million)
Table 16.268 GRASPA®: Sales Forecast for Metastatic Pancreatic Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.269 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.270 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.271 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.272 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.273 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.274 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.275 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.276 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.277 GRASPA®: Projected Opportunity for Triple Negative Breast Cancer in the US, Optimistic Scenario, till 2030 (USD Million)
Table 16.278 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, Conservative Scenario, till 2030 (USD Million)
Table 16.279 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, Base Scenario, till 2030 (USD Million)
Table 16.280 MVX-ONCO-1: Sales Forecast for Head and Neck Cancer, Optimistic Scenario, till 2030 (USD Million)
Table 16.281 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, Conservative Scenario, till 2030 (USD Million)
Table 16.282 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, Base Scenario, till 2030 (USD Million)
Table 16.283 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in EU5, Optimistic Scenario, till 2030 (USD Million)
Table 16.284 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, Conservative Scenario, till 2030 (USD Million)
Table 16.285 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, Base Scenario, till 2030 (USD Million)
Table 16.286 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in Rest of Europe, Optimistic Scenario, till 2030 (USD Million)
Table 16.287 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, Conservative Scenario, till 2030 (USD Million)
Table 16.288 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, Base Scenario, till 2030 (USD Million)
Table 16.289 MVX-ONCO-1: Projected Opportunity for Head and Neck Cancer in the US, Optimistic Scenario, till 2030 (USD Million)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 24Haymarket
  2. 3P Biopharmaceuticals
  3. 4D Pharma
  4. Aarhus University Hospital
  5. Acer Therapeutics
  6. Activartis Biotech
  7. Activate Immunotherapy
  8. Adaptimmune
  9. Adicet Bio
  10. ADIRA
  11. Aduro Biotech
  12. Advent Bioservices
  13. Agency for Science, Technology and Research
  14. AgenTus Therapeutics
  15. Aldagen
  16. Allele Biotechnology & Pharmaceuticals
  17. Alliance for Regenerative Medicine
  18. Allife Medical Science and Technology
  19. Allogene Therapeutics
  20. Alsace BioValley
  21. Altor BioScience
  22. ALTuCELL
  23. AlzeCure Pharma
  24. Amgen
  25. Amphera
  26. AMVALOR
  27. Anhui Kedgene Biotechnology
  28. ANI Pharmaceuticals
  29. Anterogen
  30. apceth Biopharma
  31. Arbele
  32. ARCH Venture Partners
  33. Argos Therapeutics
  34. Asahi Glass Company
  35. ASAP Ventures
  36. Asset Management Partners
  37. Astellas Institute for Regenerative Medicine
  38. Astellas Pharma
  39. Asterias Biotherapeutics
  40. AstraZeneca
  41. Atara Biotherapeutics
  42. Atelerix
  43. Athersys
  44. Atlanpole
  45. Atlantic Bio GMP
  46. Atreca
  47. Aurora Biopharma
  48. Australian Foundation for Diabetes Research
  49. Austrianova Singapore
  50. Autolus
  51. AVAX Technologies
  52. Axil Scientific
  53. Azellon Cell Therapeutics
  54. Bain Capital Life Sciences
  55. Bascom Palmer Eye Institute
  56. Basic Pharma
  57. Batavia Bioservices
  58. Bavarian Nordic
  59. Baxalta
  60. Baxter International
  61. Baylor College of Medicine
  62. BBS Nanotechnology
  63. Beijing Biohealthcare Biotechnology
  64. Beijing Doing Biomedical
  65. Beijing Immunochina Medical Science & Technology
  66. Beijing Sanwater Biological Technology
  67. Beijing Tricision Biotherapeutics
  68. Beike Biotechnology
  69. Bell Biosystems
  70. Bellicum Pharmaceuticals
  71. Beta-Cell
  72. Betalin Therapeutics
  73. Beta-O2 Technologies
  74. Beyond Type 1
  75. Bio Elpida
  76. BioAtla
  77. BioCardia
  78. Bioencapsulation Research Group
  79. Bioglex
  80. Bioinova
  81. Bioinspired Solutions
  82. BioLamina
  83. Bioneer
  84. BioNTech
  85. Biopredic
  86. BioRestorative Therapies
  87. BioTalentum
  88. BIOTECanada
  89. Biotechnology Innovation Organization
  90. bluebird bio
  91. Bone Therapeutics
  92. Bpifrance
  93. Brainstorm Cell Therapeutics
  94. Brammer Bio
  95. Brigham and Women's Hospital
  96. Bristol-Myers Squibb
  97. Broad Institute
  98. Brown University
  99. Caladrius Biosciences
  100. California Institute for Regenerative Medicine
  101. Calvert Crossland
  102. Cambridge Enterprise
  103. Capella Science
  104. Capricor Therapeutics
  105. Capsulæ
  106. Captain T Cell
  107. CardioCell
  108. Carina Biotech
  109. CARsgen Therapeutics
  110. Cartherics
  111. Casa Sollievo della Sofferenza
  112. Case Western Reserve University
  113. CBD Solutions
  114. Celgene
  115. Celixir
  116. Cell and Gene Therapy Catapult
  117. Cell Biotech
  118. Cell Cure Neurosciences
  119. Cell Genesys
  120. Cell Medica
  121. Cell Tech Pharmed
  122. Cellectis
  123. CellforCure
  124. Cellin Technologies
  125. CELLINK
  126. CellMed Health
  127. CellPraxis Bioengeneering
  128. CellProtect Biotechnology
  129. CellProtect Nordic Pharmaceuticals
  130. CellProthera
  131. Cells for Cells
  132. Cellular Biomedicine Group
  133. Cellular Dynamics International
  134. Cellular Therapeutics
  135. Celularity
  136. Celyad
  137. Censo Biotechnologies
  138. Centre for Brain Research at the University of Auckland
  139. Centre for Cell and Gene Processing
  140. Centre for Commercialization of Regenerative Medicine
  141. Cesca Therapeutics
  142. Chamow & Associates
  143. Chardan Capital Markets
  144. Chengdu MedGenCell
  145. Children's Hospital of Philadelphia
  146. Children's Medical Center
  147. CiMaas
  148. Clinical Network Services
  149. Cognate Bioservices
  150. Conkwest
  151. Cook Myosite
  152. Corestem
  153. Cornell University
  154. Covance
  155. Cowen Healthcare Investments
  156. CRISPR Therapeutics
  157. CRMI
  158. Cryosite
  159. CTI Clinical Trial and Consulting Services
  160. Cytopeutics
  161. Cytori Therapeutics
  162. Cytosen Therapeutics
  163. CytoSolv
  164. Cytovac
  165. CyTuVax
  166. Daiichi Sankyo
  167. Dana-Farber Cancer Institute
  168. DanDrit Biotech
  169. DCPrime
  170. Defymed
  171. Delta-Vir
  172. Dendreon
  173. DePuy Synthes
  174. Diatranz Otsuka
  175. DiscGenics
  176. Dolomite Microfluidics
  177. Duke-NUS Medical School
  178. Durham University
  179. East West Capital Partners
  180. Ecomeris
  181. Eight Roads Ventures
  182. Eli Lilly
  183. Elios Therapeutics
  184. EMMES
  185. Emory University
  186. Encellin
  187. Endocyte
  188. Epigem
  189. EryDel
  190. Erytech Pharma
  191. Ethicon
  192. Eunice Kennedy Shriver National Institute of Child Health & Human Development
  193. Eureka Therapeutics
  194. European Foundation for the Study of Diabetes
  195. Eutilex
  196. Evotec
  197. Exostem Biotec
  198. Exploit Technologies
  199. F1 Oncology
  200. Facet Life Sciences
  201. Fate Therapeutics
  202. Ferrer Internacional
  203. Fibrocell Technologies
  204. Fisher BioServices
  205. Five Prime Therapeutics
  206. Flagship Pioneering
  207. Focus Gestioni
  208. Formula Pharmaceuticals
  209. Fortress Biotech
  210. Fox Chase Cancer Center
  211. F-Prime Capital
  212. French National Institute of Health and Medical Research
  213. FronTier Merchant Capital
  214. Gabriel Investments
  215. Gadeta
  216. Gamida Cell
  217. GC Cell
  218. Genentech
  219. Genextra
  220. Genzyme
  221. Georgia Institute of Technology
  222. GigaGen
  223. Giner Labs
  224. GlaxoSmithKline
  225. Global Cell Med
  226. Gloriana Therapeutics
  227. Glycostem Therapeutics
  228. Gradalis
  229. Graybug Vision
  230. Green Cross
  231. Greenwood Way Capital
  232. GRI Bio
  233. Guangzhou Trinomab Biotech
  234. H2M Capital
  235. Harvard Stem Cell Institute
  236. Heat Biologics
  237. Hebei Senlang Biotechnology
  238. Hebrew University of Jerusalem
  239. Hemostemix
  240. HengRui YuanZheng Bio-Technology
  241. Histocell
  242. Histogenics
  243. Hitachi Chemical Advanced Therapeutics Solutions
  244. Holostem Terapieavanzate
  245. Howard Hughes Medical Institute
  246. Hunan Zhaotai Yongren Biotech
  247. I&L Biosystems
  248. iCarTAB BioMed
  249. iCell Gene Therapeutics
  250. Imaging Endpoints
  251. Immatics
  252. Immetacyte
  253. Immune Therapeutics
  254. Immunicum
  255. ImmunoCellular Therapeutics
  256. Immunocore
  257. Immunovative Therapies
  258. Immutep
  259. IMpacting Research, INnovation and Technology
  260. ImStem Biotechnology
  261. Imvax
  262. iNanoBIT
  263. Incysus
  264. Inno Biologics
  265. Innogest Capital
  266. Innovative Cellular Therapeutics
  267. Inovio Pharmaceuticals
  268. inRegen
  269. Institute for Basic Sciences
  270. Institute of Virology at the University of Veterinary Medicine
  271. Intellia Therapeutics
  272. Intrexon
  273. Iovance Biotherapeutics
  274. Iowa State University
  275. IRCAD France
  276. Israel Innovation Authority
  277. Isto Biologics
  278. iThera Medical
  279. Ivy Life Sciences
  280. Janssen Biotech
  281. Japan Tissue Engineering
  282. JDRF
  283. Jean Lamour Institute
  284. Johns Hopkins University
  285. Johnson & Johnson
  286. Joslin Diabetes Center
  287. Juno Therapeutics
  288. Juvenile Diabetes Research Foundation
  289. JW Biotechnology
  290. JW CreaGene
  291. Kadimastem
  292. Kangstem Biotech
  293. Kangwon National University
  294. Karolinska Institutet
  295. KBI Biopharma
  296. King's College London
  297. Kiromic
  298. Kite Pharma
  299. KTH Royal Institute of Technology
  300. Legend Biotech
  301. Leland Stanford Junior University
  302. Léon Bérard Center
  303. Leucid Bio
  304. Lifecells
  305. Likarda
  306. Lincoln Park Capital Fund
  307. Lion TCR
  308. Living Cell Technologies
  309. Living Pharma
  310. Longeveron
  311. Lonza
  312. Lowy Medical Research Institute
  313. Ludwig Maximilian University of Munich
  314. Lund University
  315. LV Prasad Eye Institute
  316. Maine Medical Center
  317. Marino Biotechnology
  318. Marker Therapeutics
  319. Maryland Technology Development
  320. Massachusetts General Hospital
  321. Massachusetts Institute of Technology
  322. MaSTherCell
  323. MaxCyte
  324. MaxiVAX
  325. Mayo Clinic
  326. McGill University
  327. MED-EL
  328. Medeor Therapeutics
  329. Medical University of South Carolina
  330. Medicyte
  331. MediGene
  332. MedImmune
  333. MEDINET
  334. Medipost
  335. Mediso
  336. Medpace
  337. Medtronic
  338. MedVax Technologies
  339. Medytox
  340. Merck Serono
  341. Mesoblast
  342. Michael J Fox Foundation for Parkinson’s Research
  343. MicroMecha
  344. Miltenyi Biotec
  345. Minovia Therapeutics
  346. Moderna Therapeutics
  347. MolecuVax
  348. MolMed
  349. Moraga Biotechnology
  350. MPM Capital
  351. Multimmune
  352. Mustang Bio
  353. Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering
  354. NantKwest
  355. National Cancer Institute
  356. National Center for Advancing Translational Sciences
  357. National Council of Science and Technology, Mexico
  358. National Eye Institute
  359. National Heart, Lung, and Blood Institute
  360. National Institute of Agricultural Research
  361. National Institute of Allergy and Infectious Diseases
  362. National Institute of Arthritis and Musculoskeletal and Skin Diseases
  363. National Institute of Biomedical Imaging and Bioengineering
  364. National Institute of Dental and Craniofacial Research
  365. National Institute of Diabetes and Digestive and Kidney Diseases
  366. National Institute of General Medical Sciences
  367. National Institute of Neurological Disorders and Stroke
  368. National Institute of Rehabilitation Training and Research
  369. National Institute on Aging
  370. National Institute on Deafness and Other Communication Disorders
  371. National Institutes of Health
  372. National Institutes of Health Clinical Center
  373. National Research Council of Canada
  374. National Science Foundation
  375. Nemours Alfred I duPont Hospital for Children
  376. Neopharm
  377. Network IR
  378. Neuralstem
  379. Neurotech Pharmaceuticals
  380. New York Blood Center
  381. Newable Private Investing
  382. Newcastle University
  383. NewLink Genetics
  384. Nikon CeLL innovation
  385. Nimesis Technology
  386. Nkarta Therapeutics
  387. Nohla Therapeutics
  388. Noile-Immune Biotech
  389. Northeastern University
  390. Northern Therapeutics
  391. Northwest Biotherapeutics
  392. Novadip Biosciences
  393. NovaMatrix
  394. Novartis
  395. Novella Clinical
  396. Noveome Biotherapeutics
  397. Novo Nordisk
  398. Novoron Bioscience
  399. NSF Engineering Research Center for Cell Manufacturing Technologies
  400. Nuffield Department of Surgical Sciences at the Oxford University
  401. Ohio State University
  402. OhioHealth
  403. OiDE BetaRevive
  404. Omega Ophthalmics
  405. OncoBioMed
  406. Oncodesign
  407. One Cell Systems
  408. OneVax
  409. Ontario Institute for Regenerative Medicine
  410. Opexa Therapeutics
  411. Ophysio
  412. OptoRobotix
  413. Orchard Therapeutics
  414. Oregon Health and Science University
  415. Orphan Technologies
  416. Osiris Therapeutics
  417. Otsuka Pharmaceutical Factory
  418. Oxford BioMedica
  419. Oxford Technology Management
  420. Parkwalk Advisors
  421. Paul Langerhans Institut Dresden
  422. PCI Services
  423. PDC*line Pharma
  424. Peak Capital Advisors
  425. PersonGen BioTherapeutics
  426. Pfizer
  427. PharmaBio
  428. PharmaCell
  429. PharmaCyte Biotech
  430. Pharmicell
  431. Philadelphia VA Medical Center
  432. Philips Healthcare
  433. Pinze Lifetechnology
  434. Pique Therapeutics
  435. PL BioScience
  436. Pluristem Therapeutics
  437. Poseida Therapeutics
  438. Praxis Pharmaceutical
  439. Precision BioSciences
  440. Pregene (ShenZhen) Biotechnology
  441. Profusa
  442. Promethera Biosciences
  443. Providence Investments
  444. Queen’s University
  445. RA Capital Management
  446. Ramcon
  447. Ramot
  448. Regeneris Medical
  449. Regeneron
  450. Regeneus
  451. Regenics
  452. ReNeuron
  453. RHEACELL
  454. Rice University
  455. Roger Williams Medical Center
  456. Roslin Cells
  457. Rubius Therapeutics
  458. Sanderling Ventures
  459. Sanofi
  460. Saronic Biotechnology
  461. Scientist.com
  462. Sclnow Biotechnology
  463. Scottish Investment Bank
  464. Seattle Genetics
  465. SEMIA
  466. Semma Therapeutics
  467. Sentien Biotechnologies
  468. Seraxis
  469. Sernova
  470. Servier
  471. Shanghai Bioray Laboratory
  472. Shanghai GeneChem
  473. Shanghai Houchao Biotechnology
  474. Shanghai iCELL Biotechnology
  475. Shanghai Longyao Biotechnology
  476. Shanghai Unicar-Therapy Bio-medicine Technology
  477. Shenzhen BinDeBio
  478. Shenzhen Hornetcorn Biotechnology
  479. Sherpa InnoVentures
  480. Shionogi
  481. Sidney Kimmel Cancer Center
  482. Sigilon Therapeutics
  483. Sigma-Aldrich
  484. Single Cell Technology
  485. Sinobioway Cell Therapy
  486. Skanderbeg Capital Advisors
  487. SMT Bio
  488. Sofinnova Partners
  489. Sorrento Therapeutics
  490. Sotio
  491. Sphere Fluidics
  492. SpherIngenics
  493. SQZ Biotechnologies
  494. Stanford University
  495. Statistecol Consultants
  496. Stem Cell Arabia
  497. StemBios Technologies
  498. STEMCELL Technologies
  499. Stemedica Cell Technologies
  500. Stempeutics Research
  501. Super-T Cell Cancer
  502. Surface Oncology
  503. Swiss Cancer League
  504. Swiss Group for Clinical Cancer Research
  505. Sylvatica Biotech
  506. SymbioCellTech
  507. Symbiose Biomaterials
  508. Tactiva Therapeutics
  509. Taiwan Bio Therapeutics
  510. Takara Bio
  511. Takeda Pharmaceutical
  512. Targazyme
  513. TC BioPharm
  514. TCR2 Therapeutics
  515. Technocampus Group
  516. Tella
  517. Terumo
  518. Tessa Therapeutics
  519. Teva Pharmaceutical
  520. TheraCyte
  521. Thermo Fisher Scientific
  522. Thomas Jefferson University
  523. Tianhe Stem Cell Biotechnologies
  524. Tianjin Ever Union Biotechnology 
  525. TiGenix
  526. TILT Biotherapeutics
  527. Tmunity Therapeutics
  528. TNK Therapeutics
  529. TotipotentRX
  530. TPG Capital
  531. TRACT Therapeutics
  532. TransCure BioServices
  533. Translational Drug Development
  534. Trinity College Dublin 
  535. Triumvira Immunologics
  536. Tufts University
  537. Tulane University
  538. TVAX Biomedical
  539. TxCell
  540. United States Department of Veterans Affairs
  541. Universal Cells
  542. University Health Network
  543. University of Alabama, Birmingham
  544. University of Alberta
  545. University of Arizona
  546. University of British Columbia
  547. University of California
  548. University of Cambridge
  549. University of Chicago
  550. University of Connecticut
  551. University of Delaware
  552. University of Florida
  553. University of Life Sciences, Lublin
  554. University of Lorraine
  555. University of Los Andes
  556. University of Louvain
  557. University of Massachusetts Medical School
  558. University of Miami
  559. University of Michigan
  560. University of North Carolina
  561. University of Northern Colorado
  562. University of Pennsylvania
  563. University of Perugia
  564. University of Pittsburgh
  565. University of Rochester
  566. University of Strathclyde
  567. University of Texas Southwestern Medical Center
  568. University of Veterinary Medicine, Vienna
  569. University of Virginia
  570. University of Wisconsin Madison
  571. University of Zurich
  572. Unum Therapeutics
  573. Uppsala University Hospital
  574. US Department of Defense
  575. US Stem Cell
  576. UZ Brussel
  577. UZ Leuven
  578. Vaccinogen
  579. Valorial
  580. Vanderbilt University Medical Center
  581. VEGEPOLYS
  582. Vericel
  583. ViaCyte
  584. ViCapsys
  585. ViroMed
  586. ViruSure
  587. Viscofan BioEngineering
  588. Vissum
  589. Vor Biopharma
  590. W L Gore & Associates
  591. Waisman Biomanufacturing
  592. Wake Forest School of Medicine
  593. Werth Family Investment Associates 
  594. Whitehead Institute for Biomedical Research
  595. WiSP Wissenschaftlicher Service Pharma
  596. Wuhan Sian Medical Technology
  597. Wuxi AppTec
  598. Wyss Institute for Biologically Inspired Engineering
  599. Xcelthera
  600. Xellbiogene
  601. XEME Biopharma
  602. YposKesi
  603. Zelluna Immunotherapy
  604. Zhongguancun Lianchuang Medical Engineering Transformation Center
  605. Zimmer Biomet
  606. ZIOPHARM Oncology

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com